Eric Lander talks CRISPR and the infamous Nobel ‘rule of three’
By Joel Achenbach,
The Washington Post
| 04. 21. 2016
Untitled Document
“Funny tensions in science.” That’s a phrase from the lips of Eric Lander, president and founding director of the Broad Institute of MIT and Harvard.
He was in Washington earlier this week to appear at the Aspen Institute in conversation with journalist/biographer Walter Isaacson, and inevitably the talk turned to CRISPR, the revolutionary gene-editing technique, and to Lander’s controversial essay earlier this year in the journal Cell, “The Heroes of CRISPR.” The scientific community's reaction highlighted the aforementioned funny tensions; as my colleague Carolyn Johnson reported, Lander's review of the history of CRISPR set off an epic social-media kerfuffle.
In the essay, Lander distributed credit widely for the CRISPR discovery – which rankled some parties who thought they deserved more attention, or felt that Lander had overemphasized the contribution of one of his Broad Institute colleagues. He described CRISPR as the result of many converging innovations, rather than as something that erupted in a classic Eureka! moment. (In this sense, CRISPR is like the computer; as my friend Walter's book "The Innovators" points out, no single person...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...